Moderna Awaits FDA Decision on mRNA-Based Flu Vaccine

Moderna is on the verge of discovering if its mRNA-based influenza vaccine will receive regulatory approval. This decision will significantly impact the future of mRNA research. FDA’s ruling on this novel vaccine will have serious implications.

The FDA’s Initial Rejection

In February, Moderna’s president, Stephen Hoge, encountered an unexpected situation. Charbel Haber, the head of regulatory affairs, delivered surprising news. The FDA had declined to review Moderna’s application for its mRNA flu shot. This happened despite the agency’s prior assurance to conduct a review.

“Charbel came up to me with a very nervous look on his face,” Hoge stated. “And when your head of regulatory arrives with concern, it’s serious.”

Immediately after this setback, Moderna took public action. The news and the FDA’s backtrack caused an industry stir. Soon, the FDA reconsidered and agreed to evaluate the vaccine with an added study condition. By June, FDA advisers recommended its approval. The FDA now faces a Wednesday deadline to make a final decision.

Industry Concerns and Financial Implications

The FDA’s change of mind in February created concern among investors. Rena Conti, a health economist, stresses the U.S. market’s financial significance for biotech firms. They rely on the FDA’s fair assessments to ensure returns on their investments.

“Investors don’t want to risk funds if there’s little chance of earning returns,” Conti remarked.

The Department of Health and Human Services also canceled nearly $500 million in mRNA research funding last summer. The move added to market uncertainty. Health Secretary Robert F. Kennedy Jr. has been known to doubt mRNA vaccine utility.

An HHS spokesman reiterated: “Under Secretary Kennedy’s leadership, HHS is advancing through evidence-based science and innovation.”

Impact on Venture Capital and Small Biotechs

Jeff Coller at Johns Hopkins notes that Moderna’s challenges deter smaller biotechs backing mRNA therapies. These ventures manage small teams and depend heavily on venture capital.

“If the FDA refuses Moderna, what chance do smaller firms have?” Coller questioned.

The FDA’s evaluation decisions and the HHS funding cuts have made venture capitalists cautious.

Personal Stories Reflect Broader Concerns

Janusz Racz, a retired computer scientist from London, views the mRNA technology as life-saving. Diagnosed with Stage 3 inoperable lung cancer, he joined a clinical trial for an mRNA vaccine with promising results. Regular vaccinations kept his cancer at bay.

“I saw it as a chance and wanted to contribute to give others hope,” Racz explained.

Racz reached out to Kennedy, sharing his story and stressing mRNA’s potential to save lives. He received no response.